CO2017011486A2 - Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales - Google Patents

Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales

Info

Publication number
CO2017011486A2
CO2017011486A2 CONC2017/0011486A CO2017011486A CO2017011486A2 CO 2017011486 A2 CO2017011486 A2 CO 2017011486A2 CO 2017011486 A CO2017011486 A CO 2017011486A CO 2017011486 A2 CO2017011486 A2 CO 2017011486A2
Authority
CO
Colombia
Prior art keywords
bind
heterodimeric
antibodies
antigens
domains
Prior art date
Application number
CONC2017/0011486A
Other languages
English (en)
Inventor
Gregory Moore
Matthew Bernett
Seung Chu
Rumana Rashid
Umesh Muchhal
Sung-Hyung Lee
John Deslarlais
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of CO2017011486A2 publication Critical patent/CO2017011486A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención proporciona anticuerpos heterodiméricos que se unen a dos antígenos diferentes, por ejemplo, los anticuerpos son “biespecíficos”, ya que se unen a dos antígenos diana diferentes, en general antígenos tumorales diana (TTA) como se describe más adelante. Estos anticuerpos heterodiméricos pueden unirse a estos antígenos diana de forma monovalente (por ejemplo, hay un solo dominio de unión a antígeno tal como un par de dominios ligero variable y pesado variable) o de forma bivalente (hay dos dominios de unión a antígeno que se unen cada uno independientemente al antígeno). Los anticuerpos heterodiméricos de la invención se basan en el uso de diferentes monómeros que contienen sustituciones de aminoácidos que “favorecen” la formación de heterodímeros sobre los homodímeros, como se indica con más detalles más adelante, acoplados con “variantes de pI” que permiten una purificación sencilla de los heterodímeros de entre los homodímeros, como se indica de forma similar más adelante. Para los anticuerpos biespecíficos heterodiméricos de la invención, la presente invención generalmente se basa en el uso de dominios de Fc modificados por ingeniería genética o variantes que pueden autoensamblarse en células de producción para producir proteínas heterodiméricas, y métodos para generar y purificar dichas proteínas heterodiméricas.
CONC2017/0011486A 2015-05-08 2017-11-08 Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales CO2017011486A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562159111P 2015-05-08 2015-05-08
US201562250971P 2015-11-04 2015-11-04
US201562251005P 2015-11-04 2015-11-04
PCT/US2016/029797 WO2016182751A1 (en) 2015-05-08 2016-04-28 Heterodimeric antibodies that bind cd3 and tumor antigens

Publications (1)

Publication Number Publication Date
CO2017011486A2 true CO2017011486A2 (es) 2018-03-28

Family

ID=57248331

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011486A CO2017011486A2 (es) 2015-05-08 2017-11-08 Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales

Country Status (21)

Country Link
EP (2) EP3236996B1 (es)
JP (3) JP6694446B2 (es)
KR (1) KR20180018525A (es)
CN (2) CN115536750A (es)
AU (3) AU2016262368B2 (es)
BR (1) BR112017023943A2 (es)
CA (1) CA2984134A1 (es)
CL (1) CL2017002752A1 (es)
CO (1) CO2017011486A2 (es)
CR (1) CR20170511A (es)
EA (1) EA036156B1 (es)
EC (1) ECSP17081420A (es)
HK (1) HK1244219A1 (es)
IL (1) IL255221A0 (es)
MA (1) MA41279A (es)
MX (1) MX2017014353A (es)
PE (1) PE20180188A1 (es)
PH (1) PH12017502019A1 (es)
SG (1) SG11201708620QA (es)
TN (1) TN2017000470A1 (es)
WO (1) WO2016182751A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
MA55043A (fr) 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
MA40801A1 (fr) 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
PE20180188A1 (es) 2015-05-08 2018-01-23 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017210443A1 (en) * 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
KR102523402B1 (ko) 2016-06-14 2023-04-19 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3630839A1 (en) 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
AU2018290237A1 (en) 2017-06-22 2020-01-16 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
US20190365861A1 (en) * 2018-04-18 2019-12-05 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
KR20210005683A (ko) * 2018-04-27 2021-01-14 노파르티스 아게 Cd123 및 cd3에 결합하는 이중특이적 항체의 투약
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
CA3102256A1 (en) * 2018-06-01 2019-12-05 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
CN113660956A (zh) * 2019-01-28 2021-11-16 Ab诊疗公司 双特异性抗体及其用途
CN114173875A (zh) * 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
TW202100559A (zh) 2019-05-21 2021-01-01 瑞士商諾華公司 Cd19 結合分子及其用途
AU2020279224A1 (en) 2019-05-21 2021-12-16 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2021231969A1 (en) * 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
MX2023005234A (es) 2020-11-06 2023-05-18 Novartis Ag Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
CN115894701A (zh) * 2021-09-30 2023-04-04 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
CA3233696A1 (en) * 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
WO2023215674A1 (en) * 2022-05-03 2023-11-09 Xencor, Inc. Methods for treating lymphoma
CN116375859A (zh) * 2023-06-05 2023-07-04 北京大学第一医院 一种抗vWF/PF4蛋白的单克隆抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459007A (en) 1891-09-08 Porte
US459001A (en) 1891-09-08 Hydrostatic scale
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
EP1490677A4 (en) 2002-02-27 2006-01-18 California Inst Of Techn COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
EP2322569B1 (en) 2003-10-09 2020-08-26 Ambrx, Inc. Polymer derivatives for the selective modification of proteins
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JPWO2009110132A1 (ja) 2008-03-06 2011-07-14 富士電機株式会社 アクティブ・マトリクス型表示装置
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
WO2013070565A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9701759B2 (en) * 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
AU2014205086B2 (en) * 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
CN105377889B (zh) * 2013-03-15 2020-07-17 Xencor股份有限公司 异二聚体蛋白
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
MA55043A (fr) * 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
PE20180188A1 (es) 2015-05-08 2018-01-23 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales

Also Published As

Publication number Publication date
CN115536750A (zh) 2022-12-30
AU2021203049B2 (en) 2023-06-29
EP4059514A1 (en) 2022-09-21
AU2016262368A1 (en) 2017-11-16
CN108025046B (zh) 2022-04-08
JP2023113868A (ja) 2023-08-16
SG11201708620QA (en) 2017-11-29
JP2020125326A (ja) 2020-08-20
PE20180188A1 (es) 2018-01-23
EP3236996B1 (en) 2022-03-16
JP2018519263A (ja) 2018-07-19
TN2017000470A1 (en) 2019-04-12
MA41279A (fr) 2021-04-28
AU2019216719A1 (en) 2019-09-05
JP6694446B2 (ja) 2020-05-13
AU2016262368B2 (en) 2019-05-16
KR20180018525A (ko) 2018-02-21
CL2017002752A1 (es) 2018-03-23
EA036156B1 (ru) 2020-10-07
WO2016182751A1 (en) 2016-11-17
EP3236996A1 (en) 2017-11-01
AU2021203049A1 (en) 2021-06-10
CR20170511A (es) 2018-01-22
PH12017502019A1 (en) 2018-04-02
CA2984134A1 (en) 2016-11-17
MX2017014353A (es) 2018-03-27
EA201792467A1 (ru) 2018-04-30
HK1244219A1 (zh) 2018-08-03
BR112017023943A2 (pt) 2018-07-31
IL255221A0 (en) 2017-12-31
CN108025046A (zh) 2018-05-11
ECSP17081420A (es) 2019-03-29

Similar Documents

Publication Publication Date Title
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CY1124232T1 (el) Συνδετικα μορια συνδεσης pd-l1 και lag-3
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
BR112017009264A2 (pt) proteína de ligação a epítopo ou um fragmento da mesma e imunoglobulina heterodimérica ou um fragmento da mesma
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
EA201890028A1 (ru) Антитело, связывающее cd3 человека
CO2017005388A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
CR20190440A (es) Receptores de unión a antígeno mejorados
UY37127A (es) Moléculas de unión a ror1, y métodos de uso de las mismas
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201691858A1 (ru) Композиции антител для лечения опухолей
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
EA201791393A3 (ru) Антитела к erbb3 и их применение
AR092612A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
AR072571A1 (es) Composiciones monovalentes para union a cd28 y procedimientos de uso
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CO6351802A2 (es) Anticuerpos para ccr2
AR069495A1 (es) Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)